Previous Close | 13.73 |
Open | 13.73 |
Bid | 0.00 x 3100 |
Ask | 0.00 x 1400 |
Day's Range | 13.30 - 14.01 |
52 Week Range | 4.81 - 14.44 |
Volume | |
Avg. Volume | 1,706,577 |
Market Cap | 1.448B |
Beta (5Y Monthly) | 1.44 |
PE Ratio (TTM) | 27.68 |
EPS (TTM) | 0.50 |
Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 15.80 |
Subscribe to Yahoo Finance Plus to view Fair Value for CPRX
Catalyst (CPRX) delivered earnings and revenue surprises of 17.65% and 7.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53.0 Million, a 57.7% YoY Increase Cash and Short-Term Investments at June 30, 2022 were $220.8 Million, with No Funded Debt Completed Acquisition of Ruzurgi® U.S. and Mexico Commercial Rights Advanced Plans to Diversify Portfolio and Invest in Innovative Rare Disease Opportunities Provides Guidance that Full-Year 2022 Adjusted EBITDA to be Between $100-105 Million Listing New Orange Book Patent Potentially Extends FIRDAPSE Patent Protec
The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ETCORAL GABLES, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its second quarter 2022 financial results after market close on Tuesday, August 9, 2022. Catalyst's manage